TISSUE REPAIR

AGM Company Update

Tony Charara
CEO and Co-Founder

Agenda

Brief tech recap

TR Pro+® product line - product strategy and commercialisation

TR-987 drug update

Conclusion and Questions

Beta Glucans are an overlooked molecule with significant promise, known for their powerful immunomodulating pathways for over 40 years. . .we are the only company globally with a drug in development for wound healing with the most optimal molecule from this family

- **Key challenges that have affected global glucan commercialisation in wound healing**
  - Thousands of types of molecules and structures based on size, branching pattern and purity from hundreds of different sources and strains of different source species
    - Most don't work and do not have any immunomodulating effects
    - High levels of impurity not optimised for wound healing ie sterile/ infection control significant components of the cell wall eg proteins lipids may have safety implications in open wounds
    - Lack of any meaningful clinical data/success
  - Soluble vs insoluble - most of the investment has gone into soluble forms which have all failed
  - Manufacturing inconsistency

- **What we have solved with Glucorprime**
  - Based on the preclinical evidence to date, large yeast derived glucans, given their matrix structure, and receptor engagement have the most promise
  - We believe we have the most powerful immunomodulating molecule to date
  - Designed for maximum pattern recognition on macrophages
  - High levels of purity, lowest levels of extraneous cell material of any glucan produced globally. I
  - Consistency in batch to batch manufacturing with drug product quality



REM image of extracted Glucoprime from Saccharomyces cerevisiae. Particles are approx. up to 20 micrometers and retain yeast surface patterns with exposed glucan side chains. © Tissue Repair

We have patented a proprietary optimised glucan molecule by composition, structure, source and purity which we believe is the most powerful to date designed for wound healing. . . importantly with a standardised immune response for a given dose



- There are literally thousands of different types of glucan, enormous diversity coming from the many ways that the individual glucose molecules are joined together, namely:
  - i. the position on the molecule where the two adjoining glucose units are linked;
  - ii. the specific spatial direction that the linkage takes – whether it is situated above or below the adjoining glucose units; and
  - iii. the degree of branching.
- The glucan structure of yeasts stands out from other cell wall glucans because it contains a backbone of 1->3 glucose linkages with side chains that are referred to as 1->6 linkages. Thus, these glucans are referred to as (1->3)(1->6)-β-glucan.
- Importantly it also stands out over other sources by providing a matrix that acts as a large a cellular scaffold within the wound

Glucoprime doubles the number of M2 Macrophages, our MOA acts on the prized “M1:M2” transition

- There were no significant differences seen in M1 macrophage numbers at day 3 or day 7 in the two treatment groups.
- There was a significant increase of 45% in M2 macrophages seen at day 7 in the TR Pro+® treated wounds, when compared to the hydrogel treated control.









Representative staining of hydrogel and TR Pro+® treated wounds and graphs of the positive stained cell counts for M1 macrophages and M2 macrophages. For fluorescence staining, blue is nuclear staining, red staining (F4/80 antibody) macrophage and green staining of (YM1 antibody) M2 macrophages.

Manuscript submitted: Stuart Mills et al., University of South Australia

The company is pursuing two strong opportunities competing for capital and resources . . .

Core
Chronic Wounds
Late stage drug development of TR-987

Primarily raised capital for this

- Significant amount of work over 4 years on manufacturing analytics and tox/safety and several FDA meeting requests and guidance to **achieve phase III status**
- At Phase III Clinical - 2x 300 patient trials **in recruitment**
- Only drug we know of globally doing phase III drug trials in VLUS
- **c45 sites selected c24 sites active**
  C35 patients randomised 10 in screening currently
- **Target moving to 35 active sites active by Q2 2026**

Mission

Achieve a chronic wound drug label first in c30 years

Secondary
Commercialisation of a new category of wound healing and derm products
Tr Pro product line

- Started with TR Pro validated market opportunity in aesthetics
- Achieved TGA approval
- Expanded TGA indications to cover burns eczema dermatitis, acute wounds
- Working on Class I and II EU device approval for derm indications
- Developing 3 new products creating a new category of wound healing products (Tr Med, TR-S, TR-F)
- **A full product line that is a first, a category of regenerative medicine products proving direct immune response**

Provide access to a new category of regenerative wound healing products $100m revenue opportunity globally

We now need to partner or raise capital to achieve this mission

+R TISSUE REPAIR

Agenda

Brief Tech Recap

TR Pro+® product line - product strategy and commercialisation

TR-987 drug update

Conclusion and Questions

TR product line up - a new category of regenerative wound healing

TR Pro+® Gel

TR Renew Serum

TR Med Gel

TR S

TR Ferrin Gel

5 year mission

- Global revenue opportunity AUD50-AUD100m pa
- **Broad based access to a new class of regenerative medicine** products for dermatology, aesthetics and acute wound healing indications . . .a new category of broadly accessible wound healing products achieved through low level regulatory approvals . .

Australia TGA Listed Medicine	Asia, Europe, Middle East Class 1 & 2 CE Mark	US 510K
Achieved	**In process** **Lab Work Commenced for Reg Application**	**In Process** **Lab Work Commenced for Reg Application**

Extract of Dr Leiw's presentation on the launch of TR Pro

"a new disruptor of wound healing . . moves us from passive healing to active healing of wounds"



Wound burn +9 days after treatment with existing wound bandages and SOC



Same wound 10 days post treatment with TR Pro+









Internalisation of yeast-derived beta glucan particles by RAW macrophages (McCann et al. 2005)

Supercharged Macrophages (Glucoprime®) > mild immune responses by releasing growth factors for wound healing (blood vessels, fibroblasts > collagen, elastin etc)

+R TISSUE REPAIR

Tissue Repair acute wound product strategy . . .

	AESTHETICS CHANNEL		MEDICAL CHANNEL		
PRODUCTS	**TR Pro+**	**TR Renew Serum**	**TR Med**	**TR S**	**TR Ferrin**
FORMULATION	Glucoprime Carbomer Ethanol Trolamine Titanium dioxide	Glucoprime Niacinamide Hyaluronic acid Co-enzyme Q10 Panthenol	Glucoprime & Anti microbial agent	Glucoprime Silicone gel Polysiloxanes	Glucoprime Encapsulated lactoferrin
TOP LINE INDICATION	Post-procedure aftercare until skin has epithelialised	A maintenance serum to rejuvenate the skin	Wound care gel applied until the skin has epithelialized	Follow on from GlucoMed gel to manage scar formation and skin remodelling	To reduce bruising
SKUS	Hydrogel tube 10g, 30g, 50g, 200g Sample 3g	30mL	TBC	TBC	TBC

AESTHETICS CHANNEL

Aesthetic Procedures

Laser, needling, chemical peels, injection

Dermal Therapists

Cosmetic Nurses

Cosmetic Doctors

Plastic Surgeons

Dermatologists

MEDICAL CHANNEL

Medical conditions	**Surgical Procedures**	**Skin Cancer**	**Burns**	**Radiation Dermatitis**	**Hard-to heal Wounds**
Dermatitis, eczema, scar management, foot ulcers	Biopsy, curettage, wounds	Cancer removal, solar keratosis treatment, PDT	Superficial burns	Dermatitis post radiation therapy	Lacerations, bruising, hospitalised wounds (aged care facilities)
GPs			Burns HCPs		
Dermatologists				Providers RadiologyHCPs	Nurses (aged care and wound)
Skin Cancer Clinics					Aged care providers
Pharmacists					Wound HCPs
Woundcare Nurses/Clinics					Podiatrists
Podiatrists					

Tissue Repair Portfolio – Recommended Usage



Tr Pro+® commercial experience with only one SKU, “a 10 Gram Tube”

- “A boot strapped” TR sales team - achieved distribution to c200-300 clinics
- Significant revenue growth over 12 months to 30 June 25 at c178%pa (compounded monthly growth rate of 9.68% pm) to achieve c$78k per month in revenue in June 25
- Recently secured australian distributor **Advanced Cosmeceuticals**
  - access to around 2500 clinics

How do we take the TR Pro product line forward

- Validate Advanced Cosmeceuticals reach and capability
  - We are currently in a handover phase and need to validate ability for AC to replicate the growth we experienced to a wider range of clinics
  - We expect variable performance on sales during the handover period , from now until all SKUs come on line in March 2026
- Validate demand and appetite from global distributors
  - have signed a small Thai distributor starting in March (test case)
- Secure distribution for new products TR Med then TR S (secondary objective)

- Undertake a capital raise and Invest in commercial scale production (6-7m AUD) based on validating the above

Agenda

Brief Tech Recap

TR Pro+® product line - product strategy and commercialisation

TR-987 drug update

Conclusion and Questions

Phase III Trial strategy has evolved . . .
Managing our risk of the phase III trial program

Nov 2025
Total c35 patients randomised to date
10 in screening

June 2026
Target c100 patients randomised
Green light interim analysis for futility only

June 2027

Last patient randomised

Target **35** **sites active**

Prioritise completion

BG002
US Phase III trial
312 patient target
VLUS
2-12

15 sites active

c28 patients randomised

Target 30 sites active

c100 patients randomised

Continue.

Discontinue

Last patient randomised
Based on strength of data seek clarity from FDA on requirement for second trial or phase 4 post Marketing trial and other requirements for an NDA application

Fallback if second trial required - “Tip” US trial sites into second Australia trial to prioritise completion of the second trial quickly with engaged active sites already recruiting

Deprioritise completion pending BG002 milestones

BG003
AU/US Phase III trial
312 patient target
VLUS
2-12

C7 site actives

c7 patients randomised

Discontinue

Our phase II trial data showed a 60% delta over placebo in percent wound area reduction [p<0.03] . . we are powering this signal in our phase III trial with an improved design giving us conviction over a successful outcome

"I have been involved in two trials now of TR Pro+ for healing chronic wounds, and the most recent results are very encouraging - leading to a larger Phase 3 trial about to commence in Australia and the USA. There are very few products that have been shown to promote wound healing, and the unique action of TR Pro+, by stimulating macrophages, likely explains the positive results seen so far - a healing rate almost 60% greater than placebo.
We sorely need this, with over 250,000 Australians suffering from a chronic wound and often being subjected to pain, high treatment costs and stigmatization, sometimes for years. This novel approach is just what we need."

Associate Professor Michael Woodward. Current Head of Aged Care Research and the Memory Clinic at Austin Health in Melbourne, Victoria. Past President of the Australian Wound Management Association, now Wounds Australia, and Editor of their journal, Wound Practice and Research.



A note on IP . . .
Our tech is backed by a strong patent portfolio granted in the US and currently being expanded to other global territories

US Divisional Patent Glucoprime **GRANTED**
Methods of manufacture
Pub No US 11,384,160 Bl
Publication Date Jul. 12, 2022

METHOD OF MAKING A BETAGLUCAN COMPOUND

•The claims allowed cover the methods of extraction of the Glucoprime® API, there are no other known methods to produce the API to the specifications required by the FDA which link directly to potency and efficacy and in turn clinical impact

US Divisional Patent Glucoprime **GRANTED**
Composition Claims
Pub. No.: US 2023/0085802 Al
Publication Date 23 March 2023

ISOLATED BIOLOGICAL POLYSACCHARIDE COMPOUND, METHODS OF USE AND METHODS OF MANUFACTURE THEREOF

•The claims allowed are relatively broad in terms of the type of skin treatment that may be treated. The only limitation in terms of treatment is that Glucoprime is applied topically to the skin of a wound site. The broadest claim is not restricted in terms of the type of wound and what else the vehicle comprises apart from Glucoprime

US Divisional Patent Glucoprime **GRANTED**
Publication Date 23 March 2023

BIOLOGICAL POLYSACCHARIDE COMPOUND

•The claims sought in this application cover the molecule itself for any application

Regulatory Exclusivity is also available as a New Chemical Entity

Regulatory exclusivity
5 years in USA
10 years in Europe

Glucoprime® meets the FDA criteria of A New Chemical Entity (NCE). There is no drug substance currently approved globally for any indication based on Tissue Repair's engineered molecule. This provides the potential for exclusivity preventing competitors from replicating the technology.

•**USA:** The FDA defines a new chemical entity as "a drug that contains no active moiety that has been approved by FDA in any other application submitted under section 505(b) of the Act." The FDA grants exclusivity for New Chemical Entities (NCE). This exclusivity provides the licence holder of an approved new drug application protection from new competition in the marketplace for the innovation represented by its approved drug product.

•**Europe:** A chemical active substance that is not previously authorised in a medicinal product for human use in the European Union and that is from a chemical structure point of view not related to any other authorised substances should be considered as a NAS ("New Active Substance")

Agenda

Brief Tech Recap

TR Pro+® product line - product strategy and commercialisation

TR-987 drug update

Conclusion and Questions

Important notice and disclaimer

This presentation (Presentation) is dated 18/09/2023 and has been prepared by Tissue Repair Ltd (ACN 158 411 566) (Tissue Repair or the Company).

Information in this Presentation

The information in this Presentation is of a general background nature for informational purposes, is in summary form and does not purport to be complete. It does not contain all information relevant or necessary for an investment decision or that would be required to be included in a prospectus or other disclosure document under the *Corporations Act 2001* (Cth) (Corporations Act) for an offer of securities in Australia or in any other jurisdiction. The content of this Presentation is provided as at the date of this Presentation (unless otherwise stated). The information in this Presentation is subject to change without notice and, subject only to any legal obligation to do so. The Company does not have any obligation to correct or update the content of this Presentation.

Not a prospectus or offer of securities

This Presentation is not a prospectus or any other offering document under Australian law and will not be lodged with the Australian Securities Investments Commission (ASIC). This Presentation is not, and does not constitute, an invitation, offer or recommendation of securities for subscription, purchase or sale in any jurisdiction. This Presentation also does not form the basis of any contract or commitment to issue, sell or apply for securities in Tissue Repair or any of its subsidiaries.

Past and future performance

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain forward-looking statements with respect to the financial condition, operations and business of the Company and certain plans and objectives of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms “believes”, “estimates”, “anticipates”, “expects, “predicts”, “intends”, “plans”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors that because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. They are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company disclaims any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Restriction on distribution

The distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. Any recipient of this Presentation who is outside Australia must seek advice on and observe any such restrictions.

Not financial or product advice

Reliance should not be placed on the information or opinions contained in this Presentation. This presentation is for informational purposes only and is not financial product or investment advice or recommendation to acquire any securities in the Company and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Nothing contained in this Presentation constitutes investment, legal, tax or other advice. An investor is solely responsible for forming its own opinions and conclusions on such matters and the market and for making its own independent assessment of the information provided. Any investment decision should be made solely on the basis of the investor’s own enquiries and it should consider whether such an investment is appropriate to its particular investment objectives, financial situation and needs. Recipients should conduct their own research into the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this Presentation. Recipients should seek legal, financial, tax and other advice appropriate to your jurisdiction. Tissue Repair is not licensed to provide financial product advice.

An investment in securities is subject to known and unknown risks, some of which are beyond the control of Tissue Repair and its directors, including, possible loss of income and principal invested. Tissue Repair does not warrant or represent that the information in this Presentation is free from errors, omissions or misrepresentations or is suitable for an investor’s intended use. Subject to any terms implied by law and which cannot be excluded, Tissue Repair accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special damages including but not limited to loss of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by an investor as a result of any error, omission or misrepresentation in this Presentation. Tissue Repair does not guarantee any particular rate of return or the performance of the Company, nor does it guarantee any particular tax treatment.

Financial information

The Financial Information has been prepared in accordance with the recognition and measurement principles prescribed by the Generally Accepted Accounting Principles in Australia which complies with the International Financial Reporting Standards (IFRS). The Financial Information is presented in an abbreviated form. It does not include all of the presentation and disclosures required by the IFRS and other mandatory professional reporting requirements applicable to general purpose financial reports prepared in accordance with the Corporations Act or Australian law. All financial amounts contained in this Presentation are expressed in Australian currency, unless otherwise stated. Any discrepancies between totals and sums of components in tables contained in this Presentation are due to rounding.

Third party information and market data

The views expressed in this Presentation may contain information that has been derived from independent third-party reports, research, clinical papers, surveys or publicly available sources that have not been independently verified by Tissue Repair or its advisers. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Acceptance

By attending a presentation or briefing, or accepting, accessing or reviewing this Presentation you acknowledge and agree to the terms set out in this section of the Presentation titled ‘Important notice and disclaimer’. This Presentation may not be copied, disseminated, distributed, quoted, referred to or otherwise reproduced or published, in whole or in part, for any purpose without the prior written permission of Tissue Repair.